迪高替尼软膏的用法用量

The original research companies of Digotinib Ointment are Japan's JT (Tobacco) Company and Torii Pharmaceutical Company. It was approved for marketing in Japan in January 2020, providing innovative treatment options for patients with atopic dermatitis. This article will introduce in detail the standardized usage and dosage of this drug, possible adverse reactions, and medication precautions for special groups to help patients use this treatment drug correctly.

Usage and Dosage of Digotinib Ointment

The use must strictly follow the age stratification and symptom severity for individualized adjustment, and the medication must be strictly followed as prescribed by the doctor.

Adult Medication Specifications

Adult patients are recommended to use a 0.5% concentration preparation and apply it evenly to the affected area twice a day. The dosage should not exceed 5 grams each time, and the coating area should not exceed 30% of the body surface area. If there is no significant improvement after 4 weeks of treatment, re-evaluation is required.

Children’s medication regimen

The 0.25% preparation is preferred for children aged 2-16 years old, twice daily. For those with severe symptoms, 0.5% preparation may be considered, but the dosage limit of 5 g/time must still be observed. For infants and young children aged 6 months to 2 years old, no more than 2.5 grams per serving.

Tips and Precautions for Medication

Avoid contact with the eye area and mucous membranes, clean the affected area before applying, and apply a thin layer after the skin is dry. After symptoms improve, the frequency of medication should be gradually reduced and long-term continuous use should be avoided.

Standardized medication use is the key to ensuring efficacy and reducing adverse reactions, and medical instructions must be strictly followed.

Side effects of Digotinib ointment

Understanding the adverse reactions that may be caused by the drug can help in timely identification and treatment.

Local skin reaction

Commonly seen are irritation, erythema, itching, etc. at the application site, and some patients may develop folliculitis or contact dermatitis. These reactions are usually mild and can be relieved by adjusting the medication.

Risk of secondary infection

Long-term use may increase the chance of local bacterial and viral infection, manifesting as herpetiform skin lesions or pustules. If signs of infection appear, medication should be suspended and anti-infective treatment should be carried out.

Systemic adverse reactions

Although systemic absorption is limited, individual sensitive patients may experience systemic symptoms such as headache and fatigue and require close observation.

Most adverse reactions can be controlled by adjusting the medication regimen. Severe reactions require prompt medical treatment.

Use of Digotinib Ointment by Special Populations

Use by special populations with special caution and adjust the treatment plan if necessary.

Pregnant and lactating women

Use by pregnant women only when the benefits clearly outweigh the risks. Breastfeeding women are advised to suspend breastfeeding to prevent the drug from affecting the baby through milk.

Pediatric patients

The dosage must be strictly limited for infants and young children under 2 years old, and it is prohibited for newborns. Regularly assess growth and development during treatment and avoid long-term use of high concentrations.

Elderly patients

The skin barrier function of the elderly is weak. It is recommended to start with low concentrations and closely monitor skin reactions. People with liver and kidney dysfunction should use it with caution.

Special groups need to fully weigh the pros and cons when using medication and implement individualized treatment plans.